 |
32 Diseases |  |
5 Trials |
|
5 Trials |  |
1782 News |  |
| «12...234567891011121314» |
- Daklinza (daclatasvir) / BMS
Combination therapy: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=0, Available, Sponsor: Bristol-Myers Squibb
- | Daklinza (daclatasvir) / BMS
New P1 trial: Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants (clinicaltrials.gov) - Jun 7, 2014
P1, N=28, Recruiting, Sponsor: Bristol-Myers Squibb
- Daklinza (daclatasvir) / BMS
Enrollment open: Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants (clinicaltrials.gov) - Jun 5, 2014
P1, N=28, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (clinicaltrials.gov) - Jun 4, 2014
P1, N=12, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | INX 189 / BMS, Daklinza (daclatasvir) / BMS
Trial termination: Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (clinicaltrials.gov) - May 12, 2014
P2, N=210, Terminated, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Completed --> Terminated; Termination of study was due to safety reasons
- INX 189 / BMS, Daklinza (daclatasvir) / BMS
Trial withdrawal: Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C (clinicaltrials.gov) - May 7, 2014
P2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Completed --> Terminated; Termination of study was due to safety reasons Suspended --> Withdrawn
- INX 189 / BMS, Daklinza (daclatasvir) / BMS
Enrollment change: Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C (clinicaltrials.gov) - May 7, 2014
P2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Suspended --> Withdrawn N=360 --> 0
- |||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
Trial primary completion date, Combination therapy: DIMENSION: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat na (clinicaltrials.gov) - May 6, 2014
P3, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
N=360 --> 0 Trial primary completion date: Jan 2016 --> Dec 2015
- |||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
Trial primary completion date, Combination therapy: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment na (clinicaltrials.gov) - May 6, 2014
P3, N=450, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2016 --> Dec 2015 Trial primary completion date: Jan 2015 --> Oct 2014
- || beclabuvir (BMS-791325) / BMS, Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Trial primary completion date, Combination therapy: Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications (clinicaltrials.gov) - May 6, 2014
P2, N=296, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2015 --> Oct 2014 Trial primary completion date: Feb 2014 --> Mar 2014
- ||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
Trial completion date, Combination therapy: PRINCIPAL: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (clinicaltrials.gov) - May 6, 2014
P3, N=880, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Feb 2014 --> Mar 2014 Trial completion date: Nov 2014 --> Dec 2014
- Daklinza (daclatasvir) / BMS
Trial completion date: MAGNITUDE: Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (clinicaltrials.gov) - May 6, 2014
P3, N=50, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Nov 2014 --> Dec 2014 Trial completion date: Aug 2015 --> Mar 2017
- |||| Daklinza (daclatasvir) / BMS
Trial primary completion date, Combination therapy: BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C (clinicaltrials.gov) - May 4, 2014
P3, N=246, Completed, Sponsor: Bristol-Myers Squibb
Trial completion date: Aug 2015 --> Mar 2017 Trial primary completion date: Aug 2013 --> Sep 2013
- ||| Daklinza (daclatasvir) / BMS
Trial completion date, Combination therapy: BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C (clinicaltrials.gov) - May 4, 2014
P3, N=246, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2013 --> Sep 2013 Trial completion date: Dec 2013 --> Jan 2014
- |||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus (clinicaltrials.gov) - May 4, 2014
P2, N=168, Completed, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2013 --> Jan 2014 Active, not recruiting --> Completed
- ||||||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: COMMAND-3: Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - May 4, 2014
P3, N=605, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C (clinicaltrials.gov) - May 4, 2014
P3, N=125, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C (clinicaltrials.gov) - May 4, 2014
P3, N=246, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (clinicaltrials.gov) - Apr 23, 2014
P1, N=12, Active, not recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
New P2 trial: Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO) (clinicaltrials.gov) - Apr 6, 2014
P2, N=60, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- |||| Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Enrollment open: Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO) (clinicaltrials.gov) - Apr 2, 2014
P2, N=60, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | ALS-2200 / J&J, Vertex, BMS
Enrollment closed: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (clinicaltrials.gov) - Apr 1, 2014
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| INX 189 / BMS, Daklinza (daclatasvir) / BMS
Trial initiation date: Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (clinicaltrials.gov) - Mar 9, 2014
P2, N=210, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Initiation date: Aug 2011 --> May 2012
- |||| INX 189 / BMS, Daklinza (daclatasvir) / BMS
Trial completion: Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (clinicaltrials.gov) - Mar 9, 2014
P2, N=210, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Aug 2011 --> May 2012 Suspended --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (clinicaltrials.gov) - Mar 6, 2014
P1, N=12, Active, not recruiting, Sponsor: ViiV Healthcare
- | Daklinza (daclatasvir) / BMS
Enrollment change: MAGNITUDE: Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (clinicaltrials.gov) - Jan 21, 2014
P3, N=50, Recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Completed N=95 --> 50
- ||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
Enrollment closed, Combination therapy: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment na (clinicaltrials.gov) - Jan 12, 2014
P3, N=450, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=95 --> 50 Recruiting --> Active, not recruiting
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Jan 8, 2014
P2, N=40, Recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care (clinicaltrials.gov) - Dec 3, 2013
P2, N=208, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| beclabuvir (BMS-791325) / BMS, Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Enrollment closed, Combination therapy: Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications (clinicaltrials.gov) - Nov 21, 2013
P2, N=316, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Daklinza (daclatasvir) / BMS
Trial withdrawal, Combination therapy: COMMAND-Asia: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment na (clinicaltrials.gov) - Nov 20, 2013
P3, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Daklinza (daclatasvir) / BMS
Enrollment change, Combination therapy: COMMAND-Asia: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment na (clinicaltrials.gov) - Nov 20, 2013
P3, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Withdrawn N=890 --> 0
- | INX 189 / BMS, Daklinza (daclatasvir) / BMS
Trial initiation date: Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C (clinicaltrials.gov) - Nov 7, 2013
P2, N=360, Suspended, Sponsor: Bristol-Myers Squibb
N=890 --> 0 Initiation date: Sep 2012 --> Mar 2013
- ||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
Enrollment closed, Combination therapy: PRINCIPAL: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (clinicaltrials.gov) - Nov 3, 2013
P3, N=880, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Sep 2012 --> Mar 2013 Recruiting --> Active, not recruiting
- | Olysio (simeprevir) / J&J, Medivir
New P2 trial: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Sep 8, 2013
P2, N=40, Recruiting, Sponsor: Janssen R&D Ireland
- ||||| Daklinza (daclatasvir) / BMS
Enrollment closed, IO biomarker: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus (clinicaltrials.gov) - Aug 22, 2013
P3, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
Enrollment open, Combination therapy: DIMENSION: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat na (clinicaltrials.gov) - Aug 12, 2013
P3, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Enrollment closed: QUADRIH: Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders (clinicaltrials.gov) - Aug 6, 2013
P2, N=65, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Daklinza (daclatasvir) / BMS
Trial completion: Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment (clinicaltrials.gov) - Jul 31, 2013
P1, N=36, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Completed
- Daklinza (daclatasvir) / BMS
Trial initiation date, Combination therapy: COMMAND-Asia: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment na (clinicaltrials.gov) - Jul 16, 2013
P3, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Initiation date: Apr 2013 --> Jun 2014
- |||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection (clinicaltrials.gov) - Jun 23, 2013
P2b, N=152, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Apr 2013 --> Jun 2014 Active, not recruiting --> Completed
- |||||||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
New P3 trial, Combination therapy: DIMENSION: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat na (clinicaltrials.gov) - May 30, 2013
P3, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
- | ALS-2200 / J&J, Vertex, BMS
New P2 trial: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (clinicaltrials.gov) - Apr 25, 2013
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- | Daklinza (daclatasvir) / BMS
New P1 trial: Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment (clinicaltrials.gov) - Apr 10, 2013
P1, N=36, Completed, Sponsor: Bristol-Myers Squibb
- ||||| Daklinza (daclatasvir) / BMS
Trial initiation date, IO biomarker: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus (clinicaltrials.gov) - Mar 27, 2013
P3, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Initiation date: Oct 2010 --> Dec 2011
- |||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: HEPCAT: Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (clinicaltrials.gov) - Mar 27, 2013
P2b, N=421, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 2010 --> Dec 2011 Active, not recruiting --> Completed
- Daklinza (daclatasvir) / BMS
New P3 trial, Combination therapy: COMMAND-Asia: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment na (clinicaltrials.gov) - Feb 21, 2013
P3, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
- |||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: HEPCAT: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- na (clinicaltrials.gov) - Jan 31, 2013
P2, N=395, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Daklinza (daclatasvir) / BMS
New P3 trial: MAGNITUDE: Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (clinicaltrials.gov) - Dec 3, 2012
P3, N=50, Recruiting, Sponsor: Bristol-Myers Squibb
- ||||| Daklinza (daclatasvir) / BMS
Enrollment closed, Combination therapy: COMMAND-3: Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 3, 2012
P3, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Active, not recruiting